This symposium explores who should be screened for early-stage type 1 diabetes and how findings translate into practical staging, monitoring, and care pathways. It also reviews real-world evidence on disease-modifying therapies and examines C-peptide's role as a biomarker for tracking beta-cell preservation and guiding treatment decisions.
The Early-stage T1D Care Pathway: Practical and Real-world Experience
Madrid Room, North Wing, Level 2, Allianz MiCo, Milan, Italy
Agenda
18:00–18:05 - Welcome and Introduction (Chantal Mathieu - Chair)
18:05–18:25 - A Hidden T1D Population: The Rationale for Screening Young Adults in Clinical Practice (Jeremy Pettus)
18:25–18:35 - From Detection to Care: Considerations for Real-world Early Detection Pathway Design in Adult Practices (Chantal Mathieu)
18:35–18:50 - Beta-cell Preservation in Practice: Real-world Insights and the Role of C-peptide (Marwa Tuffaha)
18:50–19:00 - Panel Discussion (All faculty)
Meeting Objectives
Examine the evidence base for targeted screening of young adults with dysglycemia and individuals with autoimmune conditions as priority populations for early-stage autoimmune type 1 diabetes (T1D) detection
Discuss practical approaches to staging, monitoring, and care pathway design for early-stage T1D in adult clinical practice
Explore the emerging real-world evidence on disease-modifying therapies in T1D
Appraise the clinical utility of C-peptide as a prospective biomarker of beta-cell preservation and treatment efficacy, as well as its implications for management on disease-modifying therapies
Welcome to BR1DGE
BR1DGE is a non-promotional global medical education program designed to advance understanding around presymptomatic type 1 diabetes and is provided by Sanofi.
This website is intended only for use by healthcare professionals in Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, India, Ireland, Israel, Italy, Japan, Kingdom of Saudi Arabia, Kuwait, Luxembourg, Mexico, Norway, Poland, Portugal, Qatar, Russian Federation, Spain, Sweden, The Netherlands, The United Arab Emirates, and The United Kingdom (UK).
Note: Healthcare professionals from Ireland or The UK must click the second link below to be redirected to the local website.
Are you a healthcare professional from one of the countries listed above?
You are now being redirected to a third-party website.
You are now being redirected to a third-party website.
You are about to leave the Sanofi-sponsored BR1DGE website and enter a third-party website. This link is provided as a service and does not imply endorsement by Sanofi of the information contained on the third-party website. Sanofi is not responsible for the content, views, or privacy policies of this third-party site.
